UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Frontiers in oncology, 2022-02, Vol.11, p.827625-827625

2022

Link zum Volltext

Verfügbarkeit prüfen

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

The New England journal of medicine, 2019-12, Vol.381 (25), p.2391-2402

2019

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer, placing drug interactions in the spotlight: Is polypharmacy the cause of everything?

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e24027-e24027

2020

Link zum Volltext

Verfügbarkeit prüfen

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.558-558

2021

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?

Clinical & translational oncology, 2021, Vol.23 (1), p.65-73

2021

Link zum Volltext

Verfügbarkeit prüfen

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

Breast cancer research : BCR, 2009-01, Vol.11 (2), p.402-402, Article 402

2009

Link zum Volltext

Verfügbarkeit prüfen

Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFR therapy

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15123-e15123

2016

Link zum Volltext

Verfügbarkeit prüfen

Concordance between radiologic and pathologic complete response in patients with breast cancer treated with neoadjuvant chemotherapy

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e12028-e12028

2014

Link zum Volltext

Verfügbarkeit prüfen

Relative bone loss during aromatase inhibitors therapy: The B-ABLE cohort

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.579-579

2014

Link zum Volltext

Verfügbarkeit prüfen

Relation of genes in estrogen and vitamin D signaling to bone mineral density loss in aromatase inhibitors treatment

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.575-575

2014

Link zum Volltext

Verfügbarkeit prüfen

Bone turnover markers at 3 months of aromatase inhibitor therapy for prediction of 1-year bone mineral density loss: The B-ABLE cohort

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.581-581

2014

Link zum Volltext

Verfügbarkeit prüfen

Preclinical in vitro and in vivo evaluation of antitumor activity of poly (ADP-ribose) polymerase inhibition and trastuzumab combined therapy in HER2-overexpressing breast cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.622-622

2014

Link zum Volltext

Verfügbarkeit prüfen

SEOM clinical guidelines for the treatment of early breast cancer

Clinical & translational oncology, 2010-11, Vol.12 (11), p.711-718

2010

Link zum Volltext

Verfügbarkeit prüfen

Pitfalls and Caveats in BRCA Sequencing

Ultrastructural pathology, 2006-05, Vol.30 (3), p.229-235

2006

Link zum Volltext

Verfügbarkeit prüfen

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

Genome medicine, 2018-03, Vol.10 (1), p.25-25, Article 25

2018

Link zum Volltext

Verfügbarkeit prüfen

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Anti-cancer drugs, 2012-02, Vol.23 (2), p.239-246

2012

Link zum Volltext

Verfügbarkeit prüfen

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

Clinical cancer research, 2017-11, Vol.23 (22), p.7006-7019

2017

Link zum Volltext

Verfügbarkeit prüfen

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

Frontiers in immunology, 2017-11, Vol.8, p.1544-1544

2017

Link zum Volltext

Verfügbarkeit prüfen

Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase II alpha Expression?: Gene, mRNA and Protein Expression: A Comprehensive Analysis

Tumor biology, 2007-09, Vol.28 (4), p.221-228

2007

Link zum Volltext

Verfügbarkeit prüfen

Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase IIα Expression?

Tumor biology, 2007-01, Vol.28 (4), p.221-228

2007

Link zum Volltext

Verfügbarkeit prüfen

The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma

Cancer genetics and cytogenetics, 2006-03, Vol.165 (2), p.151-156

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(50)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Humans
(23)
Female
(22)
Oncology
(18)
Breast Cancer
(15)
Middle Aged
(13)
Breast Neoplasms - Pathology
(12)
Adult
(11)
Aged
(10)
Breast Neoplasms - Genetics
(8)
Aged, 80 And Over
(7)
Breast Neoplasms - Drug Therapy
(7)
Spain
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Breast Neoplasms - Metabolism
(5)
Càncer
(5)
Disease Progression
(5)
Mama
(5)
Neoplasm Staging
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

Breast cancer, placing drug interactions in the spotlight: Is polypharmacy the cause of everything?

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study)

Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFR therapy

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study

Concordance between radiologic and pathologic complete response in patients with breast cancer treated with neoadjuvant chemotherapy

Relative bone loss during aromatase inhibitors therapy: The B-ABLE cohort

Relation of genes in estrogen and vitamin D signaling to bone mineral density loss in aromatase inhibitors treatment

Bone turnover markers at 3 months of aromatase inhibitor therapy for prediction of 1-year bone mineral density loss: The B-ABLE cohort

Preclinical in vitro and in vivo evaluation of antitumor activity of poly (ADP-ribose) polymerase inhibition and trastuzumab combined therapy in HER2-overexpressing breast cancer

SEOM clinical guidelines for the treatment of early breast cancer

Pitfalls and Caveats in BRCA Sequencing

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase II alpha Expression?: Gene, mRNA and Protein Expression: A Comprehensive Analysis

Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase IIα Expression?

The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma

Suchergebnisse filtern